Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 7/20 | 0.57 |
| ▸ | MAOB | P27338 | 4/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.57 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.57 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.57 |
| ▸ | HTR2C | P28335 | 2/20 | 0.42 |
| ▸ | HTR2B | P41595 | 2/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.38 |
| ▸ | MAOA | P21397 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5188008 | 1.00 | KDM1A (0.57) | KDM1AMAOBKCNH2RCOR1KDM1B | |
| SCHEMBL5187998 | 1.00 | KDM1A (0.57) | KDM1AMAOBKCNH2RCOR1KDM1B | |
| SCHEMBL21748659 | 0.81 | MEN1 (0.50) | — | |
| SCHEMBL16133827 | 0.81 | KDM1A (0.57) | KDM1AHTR2CHTR2B | |
| SCHEMBL21748652 | 0.81 | MEN1 (0.50) | — | |
| SCHEMBL16109604 | 0.81 | KDM1A (0.57) | KDM1AHTR2CHTR2B | |
| SCHEMBL21748655 | 0.81 | MEN1 (0.50) | — | |
| SCHEMBL23269920 | 0.81 | MAOB (0.54) | KDM1AMAOBKCNH2RCOR1KDM1B | |
| SCHEMBL16649958 | 0.81 | MAOB (0.54) | KDM1AMAOBKCNH2RCOR1KDM1B | |
| SCHEMBL14820115 | 0.81 | MAOB (0.54) | KDM1AMAOBKCNH2RCOR1KDM1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070270471-A1 | Compounds Which Potentiate Glutamate Receptor and Uses Thereof in Medicine | GLAXO GROUP LIMITED (GB) | 2007-11-22 | — | — | US | disclosed |
| EP-1786769-A1 | COMPOUNDS WHICH POTENTIATE GLUTAMATE RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006015827-A1 | COMPOUNDS WHICH POTENTIATE GLUTAMATE RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2006-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270471-A1 | Compounds Which Potentiate Glutamate Receptor and Uses Thereof in Medicine | GRM3, GLRA3, GLRA1 | KDM1A 3089/4885MAOB 1272/4885KCNH2 562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.